Who Makes Over the Counter Painkillers: Tylenol to Nurofen

Open any medicine cabinet in America and you will find the same four or five painkillers. What you will not find on the label is the corporate upheaval behind them. Tylenol, the best-selling analgesic in the country, is days away from changing owners for the second time in three years.

The over-the-counter analgesics market is worth about $33.5 billion and forecast to reach $55.7 billion by 2036, according to FactMR. Since 2022, nearly every brand in it has changed corporate parents, because the world's biggest drug companies decided consumer health was someone else's problem. We mapped who actually makes each painkiller on the shelf, as of November 2026.

The short version: a wave of spin-offs and one very large takeover just rewrote your medicine cabinet.

The Painkiller Map

The big branded players split the shelf by molecule. Tylenol and Motrin cover acetaminophen and ibuprofen. Advil owns the other half of ibuprofen. Aleve runs naproxen. Nurofen dominates ibuprofen across Europe and Australia. Bayer still sells the aspirin it invented in 1897.

The corporate map looks nothing like the brand map. Tylenol is a Kenvue brand, not a Johnson & Johnson brand, and Kenvue itself is being absorbed by Kimberly-Clark. Advil belongs to Haleon, the consumer health company GSK spun out in 2022. Only Bayer and Reckitt kept their painkillers in-house the whole time.

Kenvue: The J&J Spin-Off Being Acquired

Johnson & Johnson spun off its entire consumer health division as Kenvue (NYSE: KVUE) in May 2023, one of the largest IPOs of the decade. Kenvue inherited Tylenol, Motrin, Listerine, Neutrogena, Band-Aid, and Johnson's Baby.

Tylenol's own history already involved a corporate handoff. McNeil Laboratories introduced it in 1955, and Johnson & Johnson bought McNeil in 1959, which means the brand has now changed corporate parents twice in seventy years: once into J&J, once out of it into Kenvue, with a third custodian arriving this week.

Tylenol alone holds an estimated 25 to 30% of US analgesic dollar sales, which made Kenvue the branded category leader the day it listed. It also made Kenvue a target.

On November 3, 2025, Kimberly-Clark announced it would acquire Kenvue in a cash-and-stock deal valuing the company at nearly $49 billion including debt. The merger creates ten billion-dollar brands in one portfolio: Huggies, Kleenex, and Cottonelle on the K-C side, Tylenol, Listerine, Neutrogena, and Johnson's Baby on the Kenvue side. As of this writing the deal is in its final days, with Kenvue shares expected to stop trading in early November 2026.

Kimberly-Clark is betting $1.9 billion in cost synergies that it can run consumer health better as a consumer goods company than J&J could as a pharma giant. It also inherits the legal and reputational questions that have swirled around Tylenol since late 2025, when federal officials publicly questioned acetaminophen safety and litigation followed. K-C says it evaluated the risk and proceeded anyway.

Haleon: The GSK Spin-Off

Haleon (NYSE: HLN) is the other spin-off giant. GSK separated its consumer health arm in July 2022, creating what is now the world's largest standalone consumer health company, with roughly $13 billion in annual revenue.

Haleon's painkiller bench is the deepest in the industry: Advil for ibuprofen, Panadol for acetaminophen outside the US, and Voltaren for topical diclofenac. Advil alone generates an estimated $800 million or more annually, and Haleon also owns Sensodyne, Centrum, Theraflu, and TUMS.

The ownership trail has one more wrinkle. Pfizer held a large minority stake from the original GSK-Pfizer consumer joint venture, then sold out completely in early 2025 for more than $3 billion. Haleon is now fully independent, the purest play on consumer self-care in public markets.

Bayer: The Aspirin Pioneer

Bayer AG (XETRA: BAYN) is the constant. It invented aspirin in 1897, still sells Bayer Aspirin today, and holds the naproxen franchise through Aleve, the "all day" pain reliever that competes on duration rather than milligrams.

Bayer sits at an estimated 12 to 16% of the branded analgesics market, and unlike J&J and GSK it never spun its consumer health arm off, despite years of investor pressure and the distraction of the Monsanto litigation. The same company that makes Aleve also makes Roundup and a global pharma portfolio, which makes Bayer the most unusual corporate parent on the painkiller shelf.

Reckitt: The Nurofen Brand

Reckitt (LON: RKT), the British company behind Lysol, Dettol, and Finish, owns Nurofen, the ibuprofen brand that leads the category across the UK, Europe, and Australia.

Nurofen holds an estimated 10 to 14% of the global branded analgesics market and wins on format rather than molecule: combination products like Nurofen Dual Action, which pairs ibuprofen with acetaminophen in one tablet, plus targeted variants for period pain, migraines, and joint pain. Reckitt has been expanding e-pharmacy partnerships across Europe, pushing the brand deeper into markets where US names like Advil barely register.

The Consumer Health Spin-Off Wave

The pattern is the story. In four years, the biggest pharma names all reached the same conclusion:

• 2022: GSK spins out Haleon (Advil, Sensodyne, Centrum)
• 2023: Johnson & Johnson spins out Kenvue (Tylenol, Listerine, Neutrogena)
• 2025: Sanofi sells control of Opella (Allegra, Dulcolax) to CD&R, keeping a minority stake
• 2026: Kimberly-Clark acquires Kenvue outright for ~$49 billion

The drug companies kept the prescription business and offloaded the shelf-stable consumer brands to whoever wanted them. First the spin-offs separated the assets. Now the second wave, consolidation, is combining them again under consumer goods parents.

The Private Label Threat

Here is the number that explains why brands keep fighting: private-label and generic products already account for an estimated 35 to 45% of OTC analgesic unit sales. The store-brand ibuprofen next to Advil is the same active ingredient at half the price.

Branded products still capture more than half of dollar sales because consumers pay for trust, and Tylenol's premium is the industry's best proof. But the gap keeps narrowing. Perrigo, the largest US store-brand manufacturer, won FDA approval in March 2025 for a store-brand equivalent of Advil Dual Action, meaning even the innovation plays get copied within a few years.

The analgesics aisle is the same battle as the battery aisle: brand versus private label, with a commodity molecule underneath.

The brands' counterattack is format innovation. Advil Dual Action combined ibuprofen and acetaminophen in one tablet. Nurofen sells targeted variants for migraines, period pain, and joint pain. Voltaren turned a prescription-strength topical into an OTC shelf category of its own. When the molecule is free for anyone to copy, the delivery mechanism is what you can still patent, market, and charge more for.

The Ownership Comparison

Sources: company filings, FactMR OTC analgesics market report, Kimberly-Clark/Kenvue merger announcement November 2025.

What This Means for Brand Ownership

Your painkillers changed parents three times in four years, and most shoppers never noticed. Tylenol went from J&J to Kenvue to Kimberly-Clark. Advil went from a GSK-Pfizer joint venture to standalone Haleon. Sanofi's brands went to private equity. The labels stayed identical because the brands, not the companies, are the asset.

The corporate logic is consistent: pharma wants patent-protected margins, consumer goods companies want household-name cash flow, and private equity wants anything with shelf presence. The next time you reach for a bottle, the real question is who is collecting on the other end. For more, read generic vs brand-name drugs, your entire medicine cabinet might be J&J, and the pharmaceutical ownership guide.

Frequently Asked Questions

Who owns Tylenol? Tylenol is owned by Kenvue, the consumer health company Johnson & Johnson spun off in May 2023. Kimberly-Clark's ~$49 billion acquisition of Kenvue, announced November 2025, is completing in early November 2026, making Tylenol a Kimberly-Clark brand.

Who owns Advil? Advil is owned by Haleon (NYSE: HLN), the world's largest standalone consumer health company, spun off from GSK in July 2022. Pfizer sold its remaining Haleon stake in early 2025.

Who owns Aleve? Aleve is owned by Bayer AG (XETRA: BAYN), the German pharmaceutical company that also invented aspirin in 1897 and still sells Bayer Aspirin today.

Are generic painkillers the same as brand-name? Yes, the active ingredients are identical. Generic acetaminophen equals Tylenol's; store-brand ibuprofen equals Advil's and Motrin's. Private labels already take 35 to 45% of unit sales, and Perrigo won FDA approval in March 2025 for a store-brand version of Advil Dual Action.

The Bottom Line

The painkiller aisle went through a complete ownership reshuffle while the packaging never changed. The lesson: in consumer health, the brand is the durable asset and the parent company is just the current custodian. Tylenol has now had three custodians in three years.

Want to check who owns what's in your cabinet? Look up Tylenol, Kenvue, or Haleon in our database.

Explore Related Brands

• Tylenol - Acetaminophen leader, moving from Kenvue to Kimberly-Clark
• Motrin - Kenvue's ibuprofen brand
• Panadol - Haleon's global acetaminophen brand
• Voltaren - Haleon's topical diclofenac line
• Nurofen - Reckitt's ibuprofen leader in Europe and Australia
• Theraflu - Haleon's cold and flu relief brand
• Band-Aid - Kenvue wound care brand moving with Tylenol to Kimberly-Clark

Browse all healthcare and pharmaceutical brands →

Sources

1. Kimberly-Clark Corporation. "Kimberly-Clark to Acquire Kenvue" and merger completion materials, November 2025-November 2026. kimberly-clark.com 2. Kenvue Inc. Investor relations and NYSE: KVUE filings, 2023-2026. 3. Haleon plc. Annual results and corporate history, haleon.com, 2022-2026. 4. FactMR. "Over the Counter (OTC) Analgesics Market Forecast to 2036." 5. Perrigo Company. FDA approval announcement for store-brand dual-action analgesic, March 2025. 6. Bayer AG and Reckitt annual reports, FY2025.

All brand ownership data verified through WhoBrands.com's research methodology. Last updated: November 1, 2026.